跳至主要内容
临床试验/EUCTR2013-003795-13-PL
EUCTR2013-003795-13-PL进行中(未招募)1 期

ong-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301 - EXIST-LT

ovartis Pharma Services AG0 个研究点目标入组 48 人开始时间: 2015年1月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Pediatric female patients who were on study treatment in study CRAD001M2301 within the past 3 months and have not reached Tanner Stage V or age 17 at the time of completion of study CRAD001M2301
  • 2. Pediatric male patients who were on study treatment in study CRAD001M2301 within the past 3 months and have not reached Tanner Stage V or age 17 at the time of completion of study CRAD001M2301.
  • 3. Written informed consent according to local guidelines.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Pediatric female patients who were on study treatment in study CRAD001M2301 and have not reached Tanner Stage V but are within 3 month of turning age 16
  • 2. Pediatric male patients who were on study treatment in study CRAD001M2301 and have not reached Tanner Stage V but are within 3 months of turning age 17
  • 3. Any patient who was pregnant prior to start of study CRAD001M2305

研究者

相似试验

进行中(未招募)
1 期
ong-term monitoring of growth and development of pediatric patients previously treated with everolimusSubependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)MedDRA version: 21.0Level: LLTClassification code 10045138Term: Tuberous sclerosisSystem Organ Class: 100000004850
EUCTR2013-003795-13-BEovartis Pharma Services AG48
招募中
不适用
ong-term observational study to assess the development of Endocrine late effects and Osteopathologies in juvenile survivors of Paediatric MalignanciesC00-D48E00-E90NeoplasmsEndocrine, nutritional and metabolic diseases
DRKS00009841niversitätsklinikum Essen1,500
进行中(未招募)
1 期
ong term follow-up study of gene therapy trial for X-linked Retinitis Pigmentosa
EUCTR2018-000425-31-Outside-EU/EEAJanssen-Cilag International NV
进行中(未招募)
1 期
ong term follow-up study of gene therapy trial for X-linked Retinitis PigmentosaX-Linked Retinitis Pigmentosa caused by mutations in the RPGR geneMedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2018-000425-31-GBMeiraGTx UK II Ltd36
进行中(未招募)
1 期
ong term follow-up study of gene therapy trial for LCA2 OPTIRPE65eber Congenital Amaurosis (LCA) caused by mutations in RPE65MedDRA version: 20.0Level: PTClassification code 10070667Term: Leber's congenital amaurosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-000898-20-GBMeiraGTx UK Ltd27